Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery
Press Release | www.prweb.com | 5 hours 33 minutes ago
PR: Sinusitis patients life is regularly impacted by acute sinusitis or chronic sinusitis, Sinus Dynamics non-invasive nasal sinus treatment with Nasal nebulizer offers the convenience of treating all types of Sinusitis without any limitation or interference associated with any sinus surgery.
Quitting Smoking Made Easy - Time For You To Breathe Easier
Press Release | www.prlog.org | 6 hours 32 minutes ago
Quitting Smoking Made Easy - Time For You To Breathe Easier. This article is about how to stop smoking. It briefly discusses the reason why cigarette smoking is habit forming. Smokers say that it is difficult to stop smoking for a lot of different reasons. This article enumerates six easy ways to
http://www.prlog.org/10426002-quitting-smoking-made-easy-time-for-you-to-breathe-easier.html
George's Marvellous Medicine
Press Release | www.bmj.com | 7 hours ago
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
http://www.bmj.com/cgi/content/short/339/nov24_2/b4971?rss=1
Delcath Systems, Inc. Sponsors Satellite Session at World Meeting of Melanoma/Skin Cancer Centers (PR Newswire)
Press Release | finance.yahoo.com | 7 hours 25 minutes ago
NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., (Nasdaq: DCTH - News) a medical technology company testing its proprietary treatment method for primary and metastatic
http://finance.yahoo.com/news/Delcath-Systems-Inc-Sponsors-prnews-1877012127.html?x=0&.v=1
AUDIO from Medialink and Pfizer Inc.: Reduce Holiday Stress to Help Ease Fibromyalgia
Press Release | www.prnewswire.com | 16 hours 22 minutes ago
AUDIO from Medialink and Pfizer Inc.: Reduce Holiday Stress to Help Ease Fibromyalgia.
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Press Release | www.pharmiweb.com | 17 hours 55 minutes ago
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease- Committee for Medicinal Products for Human Use (CHMP) Grants Accelerated AssessmentPR NewswireDUBLIN, November 24DUBL
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=11305
Infectious Disease Experts Call for 10 New Antibiotics by 2020
Press Release | www.infectioncontroltoday.com | 23 hours 32 minutes ago
The Infectious Diseases Society of America (IDSA) has asked for a commitment from the Obama administration and the European Union to further the Society s mission to achieve the development of 10 new antibiotics within the next 10 years, known as the 10 x 20 Initiative. The World Health
Pharmaceutical-Biotech Industry Investment Update: $5.6 Billion in Capital/Maintenance Began Construction in 3Q09
Press Release | www.industrialinfo.com | Nov 23, 2009
SUGAR LAND--November 23, 2009--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--The Pharmaceutical-Biotech Industry is weathering the current economic storm well, sailing through the third quarter of 2009 with $5.6 billion in construction starts. A recent survey of active
http://www.industrialinfo.com/showAbstract.jsp?newsitemID=152778
Medical News: Mammography Guidelines Intensify Healthcare Reform Debate - in Public Health &
Press Release | www.medpagetoday.com | Nov 23, 2009
WASHINGTON -- The emotional debate over a federal panel's proposal to end routine mammograms for women in their 40s has reignited controversy over a contentious healthcare reform issue: comparative ef
http://www.medpagetoday.com/PublicHealthPolicy/Washington-Watch/17151
The M&A Trend Continues: An Analysis of the Key Mergers and Acquisitions of 2009
Press Release | www.frost.com | Nov 23, 2009
The biggest mergers and acquisitions witnessed so far in 2009 have been the Pfizer-Wyeth acquisition for $68 billion, Roche-Genentech $46.8 billion, Merck-Schering Plough $41B and Gilead Sciences-CV Therapeutics $1.4B. This accounted for a total of $157 billion dollars.
http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=185479087
